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Management of PCI patients undergoing early surgery is 
still a matter of debate. Noteworthy, PCI patients require a 
dual antiplatelet therapy (DAPT), with aspirine and a 
thienopiridine (clopidogrel, prasugrel, ticagrelor), because 
of the high risk of stent thrombosis (ST), myocardial 
infarction (MI) and death, especially within the first 
month. Indeed, the number of surgical interventions after 
PCI is actually increasing, and physicians are looking for 
the best antiplatelet therapy management, in order to 
reduce both, bleeding and thrombosis risk. In this paper, 
current guidelines therapy management and new optional 
strategies to reduce the cardiovascular risk, related to early 
surgery, are discussed. 
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Percutaneous coronary intervention (PCI) is an invasive 
non-surgical cardiovascular intervention, widely used for 
the treatment of coronary artery disease (CAD), with high 
rates of success and low rates of complications (1-3). 
Since its introduction in the clinical scenario, “new 
devices” have replaced, or served as adjuncts, to the first 
plain old balloon angioplasty (POBA), including bare-
metal stents (BMS) and drug-eluting stents (DES), with 
improved efficacy and safety profile of percutaneous 
revascularization, and consequent transition from the 
balloon PCI alone to the PCI with stenting (4). However, 
because of the high thrombotic risk following stent 
deployment, patients undergoing PCI with stenting require 
a specific dual antiplatelet therapy (DAPT), with aspirin 
and a P2Y12 receptor antagonist (clopidegrel, prasugrel or 
ticagrelor), as best medical treatment for preventing 
thrombosis (5). According to the current PCI guidelines 
(6-9), in patients with stable CAD, DAPT is strongly 
recommended for at least 1 month after a BMS 
deployment or POBA, and up to 6-12 months after a DES, 
in order to reduce the risk of ischemic events following 
PCI, including stent thrombosis (ST), myocardial 
infarction (MI) and death (10-13). Nevertheless, it should 
be considered that, after acute coronary syndromes (ACS) 
(ST-elevation-MI, Non-ST-elevation-MI, unstable-
angina), the DAPT duration required is at least up to 12 
months. Nowadays, there is a prevalence of premature 
withdrawal of DAPT between 10% and 50% of patients 
underwent PCI. One of the main reasons of DAPT 
dysruption is the need of early surgery, defined as surgical 
procedure occurring within 6 weeks after BMS or within 
12 months after DES deployment (14). Interestingly, 
surgical interventions are required within 2 years in 
approximately 5% to 15% of patients undergoing PCI 
(15). Moreover, several studies confirmed that between 
4% and 8% of PCI patients require non-cardiac surgery 
within 1 year from revascularization (16-20). Thereby, the 
drugs management of patients who need surgery after PCI 
remains one of the most debated topics. This is relevant 
not only for interventional cardiologists, but also for 
general cardiologists, surgeons, anesthesiologists, and 
primary care physicians, especially because they have to 
define and to face the life threatening ischemic and 
bleeding risk (15). 
Indeed, surgical interventions are associated with a high 
bleeding risk in patients on DAPT, thus an early 
interruption of antiplatelet therapy is often required. 
Otherwise, the premature discontituation of DAPT 
exposes patients to the risk of thrombotic consequences, 
further increased by the pro-inflammatory and pro-
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thrombotic effects of surgery itself (higher platelets 
reactivity, coaugulation proteins, fibrinogen levels and 
anemia or traumathic basal conditions). Current guidelines 
regarding PCI and surgery (21), suggest interrupting 
thienopiridine 5 (clopidogrel and ticagrelor) or 7 
(prasugrel) days before surgery, without aspirin 
withdrawal, with exception for intracranial surgery or 
transurethral prostatectomy.  However, the decision to 
early interrupt, one or both antiplatlet agents, depends on 
the evaluation of the individual thrombotic/bleeding risk. 
The aim of this review is to get more inside the 
therapeutic strategies for CAD patients requiring surgery 
after PCI with stenting.  
 
ISCHEMIC COMPLICATIONS IN SURGICAL 
PATIENTS WITH PREVIOUS PCI 
 
In PCI patients, there is a higher thrombotic risk, and the 
majority of thrombotic complications occur when metal 
stent strut and/or polymeric surface are not completely 
healed. Noteworthy, this high risk of thrombus formation 
is particularly harmful in a surgical setting, considering 
the prothrombotic and inflammatory blood properties, the 
increased levels of cytokines, neuroendocrine 
inflammatory mediators, platelet counts/adhesiveness, and 
the impaired fibrinolysis in patients requiring surgery 
(Tab. 1) (22-24). In particular, ST represents the main 
potentially catastrophic event that most commonly occurs 
within the first month after stent implantation. The causes 
of ST have been carefully investigated, and it is usually 
related to some specific clinical and angiographic features 
as reported in Fig. 1 (25-29). A new standard definition of 
ST was recently proposed by the Academic Research 
Consortium (ARC), in order to compare the true rates of 
ST across different trials and registries (Tab. 2) (30). 
However, in addition to the above-mentioned independent 
risk factors of thrombotic events, some evidence 
demonstrate that the premature discontinuation of DAPT 
represents the main risk factor for ST after BMS (31) or 
DES (11), and the rebound platelet reactivity after 
discontinuation of antithrombotic drugs, has been 
advocated to induce the increased thrombotic risk in PCI 
patients undergoing surgery (32, 33). Indeed, surgery 
represents the second cause of early DAPT 
discontinuation within 1 year (21%) (15). There are 
several studies updating the ischemic perioperative 
complications in patients undergoing early surgery after 
PCI with BMS (16, 34-37) or DES (10, 18, 38-41). 
Table.1: varariables associated to pro-thrombotic state in 
PCI patients undergoing non-cardiac surgery. 
The emphasis on DAPT cessation as the trigger for early 
ischemic events in PCI patients has been recently 
Table 1. Pro-thrombotic features in surgical setting  
 
challenged. A large retrospective study analyzed 41,989 
surgical interventions occurring within 24 months after 
stent implantation (42). Furthermore, the Patterns of non-
adherence to Antiplatelet Regimens In Stented patients” 
(PARIS) registry, analysed whether, the clinical 
circumstances and reason for discontinuation of DAPT, 
may have an impact on the cardiovascular risk that 
follows PCI (43). Interestingly, this registry explored 
carefully the underlying context in which antiplatelet 
treatment was discontinued, and patients were stratified 
into different categories, according to physician-
recommended DAPT discontinuation, surgery related 
brief DAPT interruption, and early DAPT disruption due 
to uncompliance or bleedings. Surprisingly, physician-
guided discontinuation, the most common cause of DAPT 
withdrawal (40.8% within 2 years), was associated with a 
significant lower risk of major adverse cardiac events 
(MACE), probably due to treatment bias in very low 
thrombotic risk patients. Moreover, brief interruption, 
occurring in 10.5% of patients for a mean of 6 days, was 
not associated with an increased rate of thrombotic events, 
while early disruption, occurring in 14.4% of patients, was 
associated with a substantial increased risk of MACE, 
particularly within the first month after PCI. Moreover, 
the registry reported that, the majority of adverse events 
occurred while patients were on DAPT, while DAPT 
disruption did not influenced the overall cardiac outcome. 
Accordingly, a previous study by Reddy at al. (35) 
- ACUTE CORONARY SYNDROME 
- RENAL DYSFUNCTION 
- DIABETES 
- ADVANCED AGE 
- HYPERCOAGULABLE STATES (E.G. 
ANEMIA, MALIGNANCY, SURGERY) 
- LOW RESPONSE TO THIENOPIRIDINE 
- HYPERSENSITIVITY TO POLYMER 
- PERSISTENT HIGH PLATELET 
REACTIVITY 
- STENT UNDEREXPANSION 
- STENT OVERLAPPING 
- RESIDUAL DISSECTION AT THE STENT 
EDGE 
- TYPE C LESION 
- PLAQUE RUPTURE 
- DELAYED STENT STRUT HEALIN 
- HIGH LEVELS OF FIBRINOGEN AND 
COAGULATION PROTEINS 
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showed that discontinuation of antiplatelet therapy was 
not associated with perioperative MACE in 56 patients 
with prior bare-metal stenting. 
Table 2. ARC stent thrombosis classification 
 
 
On the whole, these findings are consistent with other 
studies suggesting that early DAPT interruption before 
surgery is not absolutely harmful, if aspirin is continued 
throughout the surgical intervention, and thienopyridines 
are resumed as soon as possible after surgery (32, 44). 
However, whether this concept can automatically be 
translated to all PCI patients undergoing surgery, remains 
undefined.  Indeed, investigation on the impact of DAPT 
disruption on the perioperative cardiovascular risk, should 
also consider the general individual risk profile, the type 
of CAD (ACS or stable CAD) and both, ischemic and 
bleeding risk, related to different surgical interventions. 
 
BLEEDING COMPLICATION IN SURGICAL 
PATIENTS ON ANTIPLATELET THERAPY 
 
Perioperative bleedings may occur as consequence of 
surgical procedures or as effect of antiplatelet drug 
treatment during surgery. Up to date, the causes of 
bleedings are often a matter of debate (45). Otherwise, 
there are some surgical procedures that do not increase the 
risk of bleeding, but that can be associated with bleedings 
if antithrombotic medications are in use before surgery. 
The American College of Chest Physicians guidelines for 
the perioperative management of antithrombotic therapy, 
identified a group of surgical interventions associated with 
high bleeding risk in the setting of perioperative 
anticoagulant and antithrombotic therapy (46), including 
vascular, visceral and transbronchial surgery. 
Nevertheless, minor surgical interventions like dental 
procedures, cataract surgery, dermatologic interventions, 
as well as angiographic diagnostic procedures or 
diagnostic endoscopies, can be performed under full 
antiplatelet therapy, provided that no additional bleeding 
risk exists (47-49). A meta-analysis collecting 49,590 
patients undergoing non-cardiac surgery, estimated that 
the incidence of bleeding complications, in patients on 
aspirin therapy, varies from 0% (e.g., in case of skin 
lesion excision or cataract surgery) up to 75% (e.g., in 
case of transrectal biopsy) (50). Indeed, aspirin does not 
increase the severity of bleeding, while influences the 
number of bleeding events, with exception for intracranial 
surgery and transurethral prostatectomy. On the other 
hand, further studies conducted in patients undergoing 
non-cardiac surgery, reported the increased rate of 
bleedings with perioperative continuation of both aspirin 
and P2Y12 inhibitors (35, 36, 49). Therefore, it has been 
suggested the continuation of aspirin or thienopiridine 
alone, for secondary prevention in many surgical 
interventions (51). Nevertheless, in patients undergoing 
surgical procedures in closed anatomical space (e.g. 
intracranial neurosurgery, posterior chamber of the eye, 
medullary canal etc.) or if major bleedings are expected, it 
would rather be necessary to interrupt any kind of 
antiplatelet agent from 5 to 7 days before surgery (51). 
Anyway, also the best suitable choice of P2Y12 inhibitors 
plays a role in the management of bleedings. New oral 
P2Y12 inhibitor agents, prasugrel and ticagrelor, are 
correlated to major bleedings if compared to clopidogrel. 
Prasugrel, similar to clopidogrel, binds selectively and 
irreversibly to platelet P2Y12 receptor, but has a much 
rapid and consistent platelet inhibition (52). However, the 
perioperative use of prasugrel is limited, because of the 
increased bleeding risk related to its irreversible platelets 
inhibition. Otherwise, this drug could be used after 
surgery considering its rapid and potent onset of platelets 
inhibition. Moreover, in the TRITON-TIMI-38 trial (53), 
patients with acute coronary syndromes (ACS), referred to 
coronary artery by-pass grafting (CABG) and randomized 
to receive prasugrel or clopidogrel, showed a reduction of 
ischemic events and a rate of TIMI major bleeding greater 
with prasugrel therapy. Ticagrelor, instead, is a non-
thienopyridine agent that directly and reversibly inhibits 
P2Y12 platlet receptor, with better results on platelet 
aggregation than clopidogrel. The PLATO study (54), a 
trial comparing ticagrelor versus clopidogrel in ACS 
ARC STENT THROMBOSIS CLASSIFICATION 
Definite: symptoms 
suggestive of ACS and 
angiographic confirmation 
of ST. 
Probable: any unexplained 
death within 30 days or 
target vessel MI, without 
angiographic confirmation 
of ST. 
Possible: any unexplained 
death after 30 days. 
Early: 0-30 days post 
stent implantation:           
- Acute: <24 hours          
- Subacute: 1-30 days 
Late: >30 days 
Very late: >12 months 
ARC: Academic Research Consortium; ACS: Acute 
Coronary Syndrome; ST: Stent Thrombosis; MI: Myocardial 
Infarction. 
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patients referred to invasive or non-invasive intervention, 
demonstrated MACE and ST rates reduction, and a similar 
rate of TIMI major bleeding to clopidogrel, in patients 
undergoing CABG within 7 days after last drug intake.
 













Clinical and Angiographic predictors of ST 
Incidence of ST 
 
Figure 1: Incidence of stent thrombosis (%) related to clinical and angiographic factors (Adapted from Iakovu I. et al. 
JAMA. 2005 May 4;293(17):2126-30.) 
 
 
Therefore, the advantage of ticagrelor in perioperative 
setting could be due to the short half life and to its 
reversibility (52). Current guidelines (55), thus 
recommend continuing asprin during surgical procedures, 
while interrupting clopidogrel or ticagrelor 5 days before 
surgery, and prasugrel 7 days before surgery. However, in 
case of cardiac surgery, it is essential to consider the 
additional bleeding risk factors like heparinization, pump-
induced platelet dysfunction and impaired fibrinolysis 





The perioperative antiplatelet therapy management usually 
requires the interruption of both aspirin and ADP receptor 
inhibitor. However, if DAPT is strictly required until 
surgical intervention, short-acting platelet antagonists 
should be considered, up to few hours before surgery, as 
"bridging" therapy. The rationale of the bridging therapy 
is to reduce the risk of perioperative bleedings, promising 
ischemic prevention both before surgery and in the early 
postoperative period, when many surgeons avoid to re-
introduce DAPT immediately because of the high 
bleeding risk. Unfractioned heparins or low molecular 
weight heparins (LMWH) are not optimal bridging agents, 
because endovascular thrombosis depends on platelets 
activation rather than on coagulation cascade (57). 
Otherwise, glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors, 
such as the synthetic peptides eptifibatide (58) or tirofiban 
(59), hold some characteristics of an ideal bridging agent, 
including rapid activity, potent antiplatelet effects and 
short effect duration, except abciximab, that causes a 
prolonged irreversible platelets aggregation inhibition, and 
thus should not be used perioperatively (60). However, 
there are few discordant studies about their efficacy as 
bridging drugs, and the role of GpIIb/IIIa inhibitors 
requires more investigations. In addition, the BRIDGE 
trial (61) recently considered the cangrelor, a reversible 
P2Y12 receptor inhibitor, as an ideal bridging agent in 
patients undergoing coronary artery by-pass graft 
(CABG), showing that it is valuable in this specific 
clinical setting because of its intravenously administration, 
with rapid onset and offset. Whether these findings hold 
good also for other kind of non-cardiac surgical 
interventions, is still a hypothesis, but not a proof yet.  
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The introduction of second generation DES in the clinical 
practice, demonstrated a favourable safety profile in terms 
of low rate of ST and shorter DAPT duration, when 
compared to first generation DESs. Up to date, DESs are 
being used in high-risk lesions, even if several reports 
have suggested that they may be associated with delayed 
endothelialization, localized hypersensitivity reactions, 
and late ST (62-64). In the Efficacy of Xience/Promus 
Versus Cypher to Reduce Late Loss After Stenting 
(EXCELLENT) trial (65), 6-month DAPT did not 
increase the risk of target vessel failure at 12 months after 
DES, when compared to 2-month DAPT in stratified 
analyses of patients receiving everolimus- or sirolimus-
eluting stents. In the Real Safety and Efficacy of 3 month 
dual-antiplatelet Therapy following Endeavor 
zotarolimus-eluting stent implantation (RESET) trial (66), 
a strategy of 3 month-DAPT following Endeavor 
zotarolimus-eluting stent, was found to be non-inferior in 
comparison with 12 month-DAPT following other DES, 
for the primary composite endpoint of cardiovascular 
death, MI, ST, target vessel revascularization (TVR), or 
bleeding at 12 months. Lastly, second-generation Xience-
Prime and Xience-V everolimus-eluting stents, have 
recently gained the European CE Mark approval for the 
use with DAPT for at least 3 months, and the Resolute 
Integrity zotarolimus-eluting stent for 1 month, which 
represent the shortest DAPT duration for any major DES 
in Europe. Nowadays, several new devices that could 
overcome many limitations of BMS and DES, reducing 
the risk of ST and requiring shorter DAPT duration, have 
been developed, including DES with biodegradable 
polymer which combine the advantage of the early 
antistenotic benefit of a standard DES and the long-term 
safety benefit of a BMS. Notheworthy, these new devices, 
thanks to advanced drug delivery systems and different 
struts, could be more suitable in patients referred to early 
surgery after PCI. Indeed, the newer polymer free stent 
CID OPTIMA new-generation DES, combines the 
patented polymer-free drug reservoir and the proven 
antithrombotic and prohealing integral carbofilm coating. 
The OPTIMA has no drug polymer, and the 
antiproliferative agent used (tacrolimus) (67), is carried 
directly on the stent outer surface and released inside the 
wall vessel (68). Two randomized studies investigated 
clinical outcome of Janus Flex TES implantation with 
shorter DAT duration, the JUPITER I study (69) and the 
JUPITER II trial (70). Both trials demonstrated the safety 
of this device, without abruption of thrombotic events, 
despite only 2- or 6-months DAPT course, respectively. 
Furthermore, the Multicentre registry with Antiplatelet 
TReatment two–sIX months—MATRIX Study (71), a 
prospective, multicentre registry, investigated safety and 
efficacy of Janus Flex TES, at 12-months of follow-up in 
patients undergoing PCI, with a DAPT duration of 2 or 6 
months. Results showed that Janus Flex coronary stenting, 
followed by short DAPT, is safe and feasible, with no 
difference between 2- and 6-month DAPT groups. Indeed, 
another safe and effective option in patients referred to 
PCI, with known or supposed low compliance to DAPT, 
or candidated to early surgery, is the Genous Bio-
engineered-R stent (GRS) (72). The GRS feature is the 
ability of capturing circulating endothelial-progenitor cells 
(EPCs) from the blood stream, ensuring an early stent 
strut endothelialization (73, 74). Interestingly, a pilot 
study conducted in patients who need coronary 
revascularization before undeferrable non-cardiac surgery, 
showed that, after an average antiplatelet therapy time of 
15 days, there were no cardiac events both in the 
perioperative period and at 30-day follow-up (75). 
Accordingly, the Antiplatelet therapy after Genous EPC-
capturing coroNary stenT implantatiOn — ARGENTO 
Study (76) investigated the safety and efficacy of GRS 
with ≤15-day or >15-day DAPT in patients undergoing 
PCI, with known or expected low compliance to long-term 
DAPT. No significant differences were reported between 
different DAPT timing groups, in terms of efficacy and 
safety end-points (the composit of cardiac death, any 
myocardial infarction, target vessel revascularization and 
stent thrombosis). On the whole, these new devices could 
represent an optional strategy for coronary 
revascularization in patients who need early surgical 
intervention because of their shorter DAPT required, but 
further dedicated studies need to confirm this hypothesis.  
CONCLUSIONS 
Perioperative management of antiplatelet drugs in PCI 
patients is still a critical topic. However, in case of 
elective surgery, DES should be avoided, unless a surgery 
delays up to 12 months following DES deployment. 
Otherwise, CABG, BMS or POBA should be considered 
(Fig.2). In patients with semi-urgent surgery, the decision 
to early interrupt one, or both, antiplatelet drugs (at least 
5-7 days pre-surgery), should undergo multidisciplinary 
consultation, with the evaluation of the 
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Figure 2: Previous coronary revascularization and surgery management. 
thrombotic and bleeding risk, according to the type of 
surgical intervention (low or high bleeding risk surgery). 
Nevertheless, emergent surgery should be performed with 
full antiplatelet therapy, despite the increased bleeding 
risk. Indeed, clinical practice guidelines support 
preventive strategies in order to reduce the risk of DAPT 
withdrawal in patients referred to surgery, including BMS 
implantation whenever possible. However, there are new 
optional strategies to manage PCI patients referred to 
early surgery, such as the use of dedicated devices, with 
early healing and brief DAPT, or the perioperative 
administration of GpIIb/IIIa inhibitors, which represent a 
potential pharmacological strategy to avoid stent 
thrombosis and its dramatic effects, without increasing 
surgical bleedings. Up to date guidelines supply only few 
patient- and procedure-specific recommendations, in order 
to help physicians tailoring dedicated treatment strategies, 
in the setting of early surgery following PCI. Therefore, it 
is strictly required to consider type of surgical intervention 
and to balance safety and efficacy profiles of antiplatelets 
drugs, in this particular scenario. 
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